{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T19:55:21Z","timestamp":1790798121057,"version":"4.1.0"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n                    <jats:title>Background.<\/jats:title>\n                    <jats:p>Costimulation blockade-based immunosuppression with belatacept confers improved renal function compared with calcineurin inhibitors, but comes at a cost of increased incidence and severity of early acute rejection. Strategies to limit costimulation blockade-resistant immune cells are needed. We have previously shown that the coinhibitory receptor T-cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine-based inhibitory motif domains (TIGIT) is expressed on memory T-cell subsets associated with costimulation blockade-resistant rejection in humans. Here, we aimed to determine the functional impact of TIGIT agonism on donor-reactive memory T-cell responses in the presence of costimulation blockade in a murine model of transplantation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods.<\/jats:title>\n                    <jats:p>\n                      We used an experimental transplant model in which murine recipients possess donor-reactive CD8\n                      <jats:sup>+<\/jats:sup>\n                      T cells before transplantation and were treated with either cytotoxic T-lymphocyte antigen 4 immunoglobulin (CTLA-4Ig) alone or CTLA-4Ig in the presence of an agonistic anti-TIGIT antibody.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results.<\/jats:title>\n                    <jats:p>\n                      Results demonstrated that a significant prolongation in graft survival was observed in mice treated with CTLA-4Ig plus the TIGIT agonist compared with CTLA-4Ig alone. Furthermore, the number of graft-infiltrating donor-reactive CD8\n                      <jats:sup>+<\/jats:sup>\n                      T cells was significantly decreased, and the number of splenic forkhead box P3\n                      <jats:sup>+<\/jats:sup>\n                      CD4\n                      <jats:sup>+<\/jats:sup>\n                      regulatory T cells was significantly increased, in animals treated with CTLA-4Ig + TIGIT agonist compared with CTLA-4Ig alone. Finally, CTLA-4Ig + TIGIT agonist treatment resulted in the suppression of inflammatory transcriptional programs within donor-reactive CD8\n                      <jats:sup>+<\/jats:sup>\n                      memory T cells.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions.<\/jats:title>\n                    <jats:p>These data suggest that agonism of the TIGIT coinhibitory pathway may effectively inhibit costimulation blockade-resistant memory T-cell responses.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/tp.0000000000005922","type":"journal-article","created":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T19:00:25Z","timestamp":1790794825000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Suppression of Costimulation Blockade-Resistant Memory CD8+ T cell\u2013Mediated Rejection by TIGIT Agonism"],"prefix":"10.1097","author":[{"given":"Christina R.","family":"Hartigan","sequence":"first","affiliation":[{"name":"Department of Surgery and Emory Transplant Center, Emory University, Atlanta, GA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine D.","family":"Martinez","sequence":"additional","affiliation":[{"name":"Department of Surgery and Emory Transplant Center, Emory University, Atlanta, GA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maylene E.","family":"Wagener","sequence":"additional","affiliation":[{"name":"Department of Surgery and Emory Transplant Center, Emory University, Atlanta, GA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia M.R.","family":"Bazzano","sequence":"additional","affiliation":[{"name":"Department of Surgery and Emory Transplant Center, Emory University, Atlanta, GA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katie L.","family":"Alexander","sequence":"additional","affiliation":[{"name":"Department of Surgery and Emory Transplant Center, Emory University, Atlanta, GA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mandy L.","family":"Ford","sequence":"additional","affiliation":[{"name":"Department of Surgery and Emory Transplant Center, Emory University, Atlanta, GA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,9,30]]},"reference":[{"key":"R1-20260930","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1172\/JCI200317477","article-title":"Heterologous immunity provides a potent barrier to transplantation tolerance.","volume":"111","author":"Adams","year":"2003","journal-title":"J Clin Invest"},{"key":"R2-20260930","doi-asserted-by":"crossref","first-page":"2350","DOI":"10.1111\/ajt.14350","article-title":"Increased pretransplant frequency of CD28+ CD4+ TEM predicts belatacept-resistant rejection in human renal transplant recipients.","volume":"17","author":"Cortes-Cerisuelo","year":"2017","journal-title":"Am J Transplant"},{"key":"R3-20260930","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1111\/ajt.14349","article-title":"Belatacept-resistant rejection is associated with CD28+ memory CD8 T cells.","volume":"17","author":"Mathews","year":"2017","journal-title":"Am J Transplant"},{"key":"R4-20260930","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1111\/imr.12824","article-title":"Memory T-cell exhaustion and tolerance in transplantation.","volume":"292","author":"Hartigan","year":"2019","journal-title":"Immunol Rev"},{"key":"R5-20260930","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1172\/JCI80445","article-title":"TIGIT and PD-1 impair tumor antigen-specific CD8(+) T cells in melanoma patients.","volume":"125","author":"Chauvin","year":"2015","journal-title":"J Clin Invest"},{"key":"R6-20260930","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1038\/s41590-018-0132-0","article-title":"Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity.","volume":"19","author":"Zhang","year":"2018","journal-title":"Nat Immunol"},{"key":"R7-20260930","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.immuni.2014.02.012","article-title":"Treg cells expressing the coinhibitory molecule TIGIT selectively inhibit proinflammatory Th1 and Th17 cell responses.","volume":"40","author":"Joller","year":"2014","journal-title":"Immunity"},{"key":"R8-20260930","doi-asserted-by":"crossref","first-page":"4053","DOI":"10.1172\/JCI81187","article-title":"TIGIT predominantly regulates the immune response via regulatory T cells.","volume":"125","author":"Kurtulus","year":"2015","journal-title":"J Clin Invest"},{"key":"R9-20260930","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1038\/s41467-021-21413-y","article-title":"Implication of TIGIT(+) human memory B cells in immune regulation.","volume":"12","author":"Hasan","year":"2021","journal-title":"Nat Commun"},{"key":"R10-20260930","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/ni.1674","article-title":"The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells.","volume":"10","author":"Yu","year":"2009","journal-title":"Nat Immunol"},{"key":"R11-20260930","doi-asserted-by":"crossref","first-page":"3000","DOI":"10.4049\/jimmunol.1700407","article-title":"Functional anti-TIGIT antibodies regulate development of autoimmunity and antitumor immunity.","volume":"200","author":"Dixon","year":"2018","journal-title":"J Immunol"},{"key":"R12-20260930","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1038\/s41467-020-15025-1","article-title":"TIGIT limits immune pathology during viral infections.","volume":"11","author":"Schorer","year":"2020","journal-title":"Nat Commun"},{"key":"R13-20260930","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.annonc.2021.11.002","article-title":"First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small-cell lung cancer(\u2606).","volume":"33","author":"Niu","year":"2022","journal-title":"Ann Oncol"},{"key":"R14-20260930","first-page":"1","article-title":"Tiragolumab (anti-TIGIT) in SCLC: Skyscraper-02, a towering inferno.","volume":"14","author":"Brazel","year":"2023","journal-title":"Lung Cancer (Auckl)"},{"key":"R15-20260930","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1001\/jamaoncol.2023.3867","article-title":"Anti-TIGIT antibody tiragolumab alone or with atezolizumab in patients with advanced solid tumors: a phase 1a\/1b nonrandomized controlled trial.","volume":"9","author":"Kim","year":"2023","journal-title":"JAMA Oncol"},{"key":"R16-20260930","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s00280-023-04627-3","article-title":"Phase I study of the anti-TIGIT antibody tiragolumab in combination with atezolizumab in Japanese patients with advanced or metastatic solid tumors.","volume":"94","author":"Yamamoto","year":"2024","journal-title":"Cancer Chemother Pharmacol"},{"key":"R17-20260930","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.ajt.2022.12.011","article-title":"TIGIT agonism alleviates costimulation blockade-resistant rejection in a regulatory T cell-dependent manner.","volume":"23","author":"Hartigan","year":"2023","journal-title":"Am J Transplant"},{"key":"R18-20260930","doi-asserted-by":"crossref","first-page":"3081","DOI":"10.1111\/ajt.13399","article-title":"Pathogen stimulation history impacts donor-specific CD8 T cell susceptibility to costimulation\/integrin blockade-based therapy.","volume":"15","author":"Badell","year":"2015","journal-title":"Am J Transplant"},{"key":"R19-20260930","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1084\/jem.20052237","article-title":"Secondary memory CD8+ T cells are more protective but slower to acquire a central-memory phenotype.","volume":"203","author":"Jabbari","year":"2006","journal-title":"J Exp Med"},{"key":"R20-20260930","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1172\/JCI8082","article-title":"Asialo GM1(+) CD8(+) T cells play a critical role in costimulation blockade-resistant allograft rejection.","volume":"104","author":"Trambley","year":"1999","journal-title":"J Clin Invest"},{"key":"R21-20260930","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1186\/s12967-022-03480-x","article-title":"Blocking TIGIT\/CD155 signalling reverses CD8(+) T cell exhaustion and enhances the antitumor activity in cervical cancer.","volume":"20","author":"Liu","year":"2022","journal-title":"J Transl Med"},{"key":"R22-20260930","doi-asserted-by":"crossref","first-page":"878320","DOI":"10.3389\/fimmu.2022.878320","article-title":"Increased expression of multiple co-inhibitory molecules on malaria-induced CD8(+) T cells are associated with increased function instead of exhaustion.","volume":"13","author":"Brandi","year":"2022","journal-title":"Front Immunol"},{"key":"R23-20260930","doi-asserted-by":"crossref","first-page":"556","DOI":"10.3389\/fendo.2020.00556","article-title":"Master regulator activating transcription factor 3 (ATF3) in metabolic homeostasis and cancer.","volume":"11","author":"Ku","year":"2020","journal-title":"Front Endocrinol (Lausanne)"},{"key":"R24-20260930","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1158\/0008-5472.CAN-11-3055","article-title":"RhoB differentially controls Akt function in tumor cells and stromal endothelial cells during breast tumorigenesis.","volume":"73","author":"Kazerounian","year":"2013","journal-title":"Cancer Res"},{"key":"R25-20260930","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1111\/ajt.16386","article-title":"Optimization of de novo belatacept-based immunosuppression administered to renal transplant recipients.","volume":"21","author":"Kirk","year":"2021","journal-title":"Am J Transplant"},{"key":"R26-20260930","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1111\/ajt.13613","article-title":"CD57(+) CD4 T cells underlie belatacept-resistant allograft rejection.","volume":"16","author":"Espinosa","year":"2016","journal-title":"Am J Transplant"},{"key":"R27-20260930","doi-asserted-by":"crossref","first-page":"3256","DOI":"10.1111\/ajt.16571","article-title":"TIGIT regulates apoptosis of risky memory T cell subsets implicated in belatacept-resistant rejection.","volume":"21","author":"Sun","year":"2021","journal-title":"Am J Transplant"},{"key":"R28-20260930","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/83144","article-title":"Akt provides the CD28 costimulatory signal for up-regulation of IL-2 and IFN-gamma but not TH2 cytokines.","volume":"2","author":"Kane","year":"2001","journal-title":"Nat Immunol"},{"key":"R29-20260930","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.immuni.2022.02.005","article-title":"Mechanistic convergence of the TIGIT and PD-1 inhibitory pathways necessitates co-blockade to optimize anti-tumor CD8(+) T cell responses.","volume":"55","author":"Banta","year":"2022","journal-title":"Immunity"},{"key":"R30-20260930","doi-asserted-by":"crossref","first-page":"101184","DOI":"10.1016\/j.esmoop.2023.101184","article-title":"Anti-TIGIT therapies for solid tumors: a systematic review.","volume":"8","author":"Rousseau","year":"2023","journal-title":"ESMO Open"}],"container-title":["Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/TP.0000000000005922","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T19:00:28Z","timestamp":1790794828000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/TP.0000000000005922"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,30]]},"references-count":30,"URL":"https:\/\/doi.org\/10.1097\/tp.0000000000005922","relation":{},"ISSN":["0041-1337","1534-6080"],"issn-type":[{"value":"0041-1337","type":"print"},{"value":"1534-6080","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,30]]}}}